PPARGC1A and Hypertension: The absence of miR-29 expression triggers cardiovascular fibrosis, systemic hypertension, diastolic dysfunction, and HF that can be extensively rescued by genetic approaches involving heterozygous loss of PGC1α, which is thus validated as an in vivo functional target of miR-29.